NCT01451099已完成2 期
A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of Injections of Ex Vivo Expanded Cultured Occipital Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss
Aderans Research Institute6 个研究点 分布在 1 个国家目标入组 21 人开始时间: 2009年6月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 21
- 试验地点
- 6
- 主要终点
- Change from baseline in hair number
研究概览
简要总结
Evaluate the ability of Ji Gami(TM) DO to induce hair growth in male and female subjects with hair loss.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female volunteers 18 to 65 years old, inclusive
- •Hair loss consistent with ≥ Grade III-Vertex, IV, VA, V, and VI, based on Norwood-Hamilton Scale providing there is bridging of hair in the anterior edge of the vertex circle.
- •Have no clinically significant disease or abnormal laboratory results taken at the screening visit.
排除标准
- •Known sensitivity to DMEM/F-12 or any component of the study material.
- •Known hypersensitivity to clindamycin hydrochloride, amphotericin B or streptomycin sulfate.
- •Subjects who have used minoxidil, or any oral or topical medication including over the counter and herbal medications for the treatment of hair loss within 6 months of study screening, or finasteride or dutasteride within 12 months of study screening.
- •A history of drug or alcohol abuse within 1 year of study enrollment.
- •Clinically significant medical or psychiatric illness currently or within 30 days of study screening as determined by the investigator.
- •Any clinically significant abnormal laboratory parameters.
- •A positive result at screening for human immunodeficiency virus (HIV 1 or 2), Hepatitis B or C, HTLV I/II.
- •Dermatologic condition in donation and/or study areas.
- •Prior surgery in the treatment area.
- •Insufficient hair or scarring in the donor area that might impact cell growth.
- •Any disease or condition (medical or surgical) that, in the opinion of the investigator, might compromise hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, or central nervous system function; or any condition that would place the subject at increased risk.
结局指标
主要结局
Change from baseline in hair number
时间窗: 51 weeks post-injection
Change from baseline in hair width
时间窗: 51 weeks post-injection
Time course of any treatment benefit
时间窗: 51 weeks post-injection
次要结局
未报告次要终点
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair LossMale Pattern BaldnessFemale Pattern BaldnessAndrogenetic AlopeciaNCT01451021Aderans Research Institute21
已完成
2 期
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002899)Male Pattern BaldnessFemale Pattern BaldnessAndrogenetic AlopeciaNCT01451112Aderans Research Institute30
已完成
2 期
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002012)Male Pattern BaldnessFemale Pattern BaldnessAndrogenetic AlopeciaNCT01451047Aderans Research Institute31
已完成
2 期
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0005995)Male Pattern BaldnessFemale Pattern BaldnessAndrogenetic AlopeciaNCT01451190Aderans Research Institute88
已完成
2 期
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0006931)Male Pattern BaldnessFemale Pattern BaldnessAndrogenetic AlopeciaNCT01669746Aderans Research Institute34